HDAC9 and diffuse large B-cell lymphoma: Fimepinostat, a PI3K inhibitor and HDAC inhibitor that originally received orphan drug designation for diffuse large B-cell lymphoma, is also under investigation in combination with standard treatments to confirm BBB permeability [122].